Titolo	Data di pubblicazione	Autore(i)
1	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: A combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors	2016	Kopecka, Joanna; Porto, Stefania; Lusa, Sara; Gazzano, Elena; Salzano, Giuseppina; Pinzòn-Daza, Martha Leonor; Giordano, Antonio; Desiderio, Vincenzo; Ghigo, Dario; De Rosa, Giuseppe; Caraglia, Michele; Riganti, Chiara
2	Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	2012	I. Campia; J. Kopecka; B. Castella; M. Rigoni; M. Coscia; A. Bosia; D. Ghigo; M. Massaia; C. Riganti
3	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells	2013	C. Riganti; B. Castella; J. Kopecka; I. Campia; M. Coscia; G. Pescarmona; A. Bosia; D. Ghigo; M. Massaia
4	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma	2015	IC Salaroglio; I Campia; J Kopecka; E Gazzano; S Orecchia; D Ghigo; C Riganti
5	Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5	Being printed	Milosevic V.; Kopecka J.; Salaroglio I.C.; Libener R.; Napoli F.; Izzo S.; Orecchia S.; Ananthanarayanan P.; Bironzo P.; Grosso F.; Tabbo F.; Comunanza V.; Alexa-Stratulat T.; Bussolino F.; Righi L.; Novello S.; Scagliotti G.V.; Riganti C.
6	Two repeated low doses of doxorubicin are more effective than one single high dose against tumors overexpressing P-glycoprotein	2015	C. Riganti; E. Gazzano; GR. Gulino; M. Volante; D. Ghigo; J. Kopecka
7	The “LDL-masked doxorubicin”: an effective strategy for drug delivery across hypoxic blood brain barrier	2014	ML Pinzòn-Daza; J Kopecka; I Campia; R Garzon; C Riganti
8	The Role of C/EBP-β LIP in Multidrug Resistance	2015	C. Riganti; J. Kopecka; E. Panada; S. Barak; M. Rubinstein
9	The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells.	2014	ML. Pinzón-Daza; IC. Salaroglio; J. Kopecka; R. Garzòn; PO. Couraud; D. Ghigo; C. Riganti
10	Temozolomide epigenetically down-regulates Wnt3a-dependent signaling and P- glycoprotein in glioblastoma stem cells	2012	I. Campia; I.C. Salaroglio; J. Kopecka; M.L. Pinzòn; V. Caldera; D. Ghigo; A. Bosia; D. Schiffer; C. Riganti
11	Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling.	2014	C. Riganti; IC. Salaroglio; ML Pinzòn-Daza; V. Caldera; I. Campia; J. Kopecka; M. Mellai; L. Annovazzi; PO. Couraud; A. Bosia; D. Ghigo; D. Schiffer
12	Temozolomide down-regulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/GSK3/β-catenin pathway	2013	C. Riganti; IC. Salaroglio; V. Caldera; I. Campia; J. Kopecka; M. Mellai; L. Annovazzi; A. Bosia; D. Ghigo; D. Schiffer
13	Targeting mevalonate pathway down-regulates ABCB1, reversing chemoresistance and immunoresistance in human cancer cells.	2012	Joanna Kopecka; Ivana Campia; Barbara Castella; Massimo Massaia; Chiara Riganti
14	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1	2017	Pati, Maria Laura; Groza, Diana; Riganti, Chiara; Kopecka, Joanna; Niso, Mauro; Berardi, Francesco; Hager, Sonja; Heffeter, Petra; Hirai, Miwa; Tsugawa, Hitoshi; Kabe, Yasuaki; Suematsu, Makoto; Abate, Carmen
15	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells	2015	Kopecka, Joanna; Porto, Stefania; Lusa, Sara; Gazzano, Elena; Salzano, Giuseppina; Giordano, Antonio; Desiderio, Vincenzo; Ghigo, Dario; Caraglia, Michele; De Rosa, Giuseppe; Riganti, Chiara
16	Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target	2018	Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
17	Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	2018	Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
18	REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE	2017	Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
19	REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	2018	Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
20	REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	2016	Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M